India Approves First Wave of Generic Semaglutide Therapies as Novo Nordisk Patent Expires

India has entered the first wave of generic semaglutide approvals, with CDSCO clearing multiple formulations for obesity and diabetes. Domestic drugmakers including Sun Pharmaceutical Industries, Zydus Lifesciences, Alkem Laboratories, and Dr. Reddy's Laboratories have received approvals. Semaglutide, a blockbuster GLP-1 receptor agonist innovated by Novo Nordisk, is set to go off patent in March this year. The approvals pave the way for lower-cost alternatives to the innovator product.